Search results
Therapy developer Alumis seeks up to $1 billion valuation in US IPO
WSAU Wausau· 21 hours ago(Reuters) - Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday. Biotech IPOs have shown signs of ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 6 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 4 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
NBC Securities Inc. Has $1.77 Million Stake in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 5 days agoNBC Securities Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.0% in the 1st quarter, according to the company in its most recent filing with the Securities ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 6 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
1,533 Shares in AbbVie Inc. (NYSE:ABBV) Acquired by Warren Street Wealth Advisors LLC
ETF DAILY NEWS· 7 days agoWarren Street Wealth Advisors LLC acquired a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 6 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 3 days agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 6 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 5 days agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. The submission ...